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Added value of speckle tracking in the evaluation of cardiac
function in patients with sickle cell disease
Speckle tracking echocardiography is a new means of evalu-
ating cardiac function. The principle of speckle tracking is to
measure myocardial strain, based on local shortening, length-
ening and thickening of the muscles.
It has been proposed that the left ventricle global longitu-
dinal strain (LV-GLS) could be a useful tool for the detection
of early systolic dysfunction in patients under cardiotoxic
chemotherapy (Thavendiranathan et al, 2014). Moreover, the
high reproducibility of the LV-GLS represents an advantage
over the left ventricle ejection fraction (LVEF) (King et al,
2016; Medvedofsky et al, 2017). Compared to the LVEF, the
LV-GLS is less affected by changes in loading conditions,
which makes it a potentially useful tool in patients with
sickle cell disease (SCD), due to the chronic overload associ-
ated with SCD. However, in this population, studies are rare
and results are conflicting (Ahmad et al, 2012; Sengupta
et al, 2012; Barbosa et al, 2014; Hammoudi et al, 2014).
The primary aim of our study was to determine whether
the LV-GLS was abnormal in a monocentric population of
adults with SCD, compared to a matched population of
healthy individuals. The secondary aim was to investigate
correlations between the echocardiographic parameters and
the biological and clinical evaluations of patients with SCD.
The institutional Ethics Committee approved the protocol.
All patients provided informed consent.
We prospectively included 37 patients with SCD and 34
healthy, age- and sex-matched controls. The patient and con-
trol groups were similar in age (31  10 years vs.
32  10 years, respectively).
The LVEF was significantly lower in the SCD group than
in the control group (Teicholz: 618% vs. 676%; P = 005;
Simpson: 619% vs. 693%; P < 005; Table I). However, only
one patient had a Simpson LVEF < 50%. The left ventricular
(LV) mass and LV end diastolic diameter (LVEDD) were
higher in the patient group (LV mass: 107 g/m2 vs. 70 g/m2,
P < 005 and LVEDD: 53 mm vs. 46 mm; P < 005). The
myocardial performance index was higher (higher values
indicate impaired LV function) in the patient group com-
pared to the control group (038 vs. 027; P < 005). The
LV-GLS was significantly lower in the SCD group than in
the control group (194% vs. 224%; P < 005), and it
was abnormal (strain > 18%) in 8 (21%) patients of the
SCD group. Diastolic function was abnormal in three SCD
patients (8%), but normal in the entire control group. The
tricuspid regurgitation velocity was higher in the SCD group
than in the control group (224 m/s vs. 196 m/s, P < 005).
However, no patient had pulmonary hypertension.
The multivariate analysis results (Table II) showed that
only the LV-GLS and LVEDD remained significantly different
between groups.
Among patients with SCD, the mean Hb was 94 g/l
(range: 61–122 g/l) and the mean HbF was 127% (range: 1–
286%). The mean ferritin level was 644 lg/l (range: 13–
7267 lg/l). Iron overload, defined as a ferritin level greater
than 1000 lg/l, was observed in five patients. The mean N-
terminal pro b-type natriuretic peptide (NTproBNP) level
was 154 pg/ml (range 12–1685 pg/ml). The mean patient
walking distance was 66% of the predicted value (range:
33–88%).
Table I. Univariate analysis results show differences between SCD
and healthy controls.
Parameter Control SCD P
LVEF-Teicholz (%) 676  69 618  62 <005
LVEF-Simpson (%) 693  53 619  72 <005
LVEF < 50% 0 1 (27%)
MPI 027  008 038  12 <005
LV-GLS (%) 224  28 194  24 <005
LV-GLS < 18% 0 8 (21%)
TRV (m/s) 196  021 224  025 <005
E/A 163  035 157  04 NS
E0 (m/s) 016  003 015  004 NS
E/E0 564  134 644  176 NS (0054)
DT (ms) 187  36 194  37 NS
Diastolic
dysfunction
0 3 (8%) NS
LVEDD (mm) 46  49 53  51 <005
LV mass (g/m2) 70  28 107  45 <005
LVH 0 18 (48%) <005
Results are expressed as the mean  standard deviation.
DT, deceleration time of E mitral wave; E0, early diastolic mitral
annular tissue Doppler velocity; E/A, early peak diastolic velocity of
the mitral inflow/late peak diastolic velocity of the mitral inflow; E/
E0, ratio between peak velocities of mitral E wave and early-diastolic
mitral annulus; LV mass, left ventricular mass; LV-GLS, left ventricle
global longitudinal strain; LVEDD, left ventricular end-diastolic
diameter; LVEF, left ventricular ejection fraction; LVH, left ventricu-
lar hypertrophy; MPI, myocardial performance index; NS, not signif-
icant; SCD, sickle cell disease; TRV, maximal tricuspid regurgitation
velocity.
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A correlation was found between the ferritin level and the
LVEF (P = 004) and the LVEF and LV-GLS (P = 0027). No
correlation was found between NTproBNP level and LVEF
(P = 0569) NTproBNP and LV-GLS (P = 0859), walking
distance test and LVEF (P = 02) and walking distance test
and LV-GLS (P = 0106).
Our study showed that GLS was a more powerful index of
systolic function than LVEF in patients with SCD. Indeed,
the GLS was abnormal in 8 (21%) of 37 patients; in contrast,
the LVEF was abnormal in only one of these patients. We
could not find a correlation between LV-GLS and the walk-
ing distance test or the NTproBNP level. The small number
of patients included in the study might explain these results.
Furthermore, walking distance test can also be influenced by
anaemia, as could be NTproBNP level (Karakoyun et al,
2017).
We conclude that the LV-GLS, an emerging sensitive and
reproducible parameter of systolic function, appeared to be
an effective tool for the detection of early systolic dysfunc-
tion in patients with SCD.
However, the clinical impact of an altered LV-GLS in
patients with SCD remains to be assessed: larger studies, with
a longer follow-up, should be conducted to confirm our
results and to evaluate whether LV-GLS might have prognos-
tic implications and whether it should be recommended in
routine evaluations of these patients.
Author’s contributions
MM, MAA, and AE designed the study; MM and TBH per-
formed the research; MM and JCR analysed the data; MM
and JCR wrote the paper. All authors were involved in
manuscript preparation and approved the final version of the
manuscript.







1Departement de cardiologie, service de Medecine Interne, CHU Brug-
mann, 2Departement d’hemato-oncologie, service de Medecine Interne,
CHU-Brugmann, and 3Departement de recherche Clinique, CHU
Brugmann, Bruxelles, Belgium.
E-mail: marielle.morissens@chu-brugmann.be
Keywords: sickle cell disease, speckle tracking, longitudinal strain,
systolic function
Table II. Multivariate analysis results show factors significantly
related to SCD.
Factors Control SCD P multivariate
LVEF-Teicholz (%) 676  69 61. 8  62 NS
LVEF-Simpson (%) 693  53 619  72 NS
MPI 027  008 038  12 NS
LV-GLS (%) 224  28 194  24 <005
TRV (m/s) 196  021 224  025 NS
E/A 163  035 157  04 NS
E0 (m/s) 016  003 015  004 NS
E/E0 564  134 644  176 NS
DT (ms) 187  36 194  37 NS
LVEDD (mm) 46  49 53  51 <005
LV mass (g/m²) 70  28 107  45 NS




Results are expressed as the mean  standard deviation.
DT, deceleration time of E mitral wave; E0, early diastolic mitral
annular tissue Doppler velocity; E/A, early peak diastolic velocity of
the mitral inflow/late peak diastolic velocity of the mitral inflow; E/
E0, ratio between peak velocities of mitral E wave and early-diastolic
mitral annulus; LV mass, left ventricular mass; LV-GLS, left ventricle
global longitudinal strain; LVEDD, left ventricular end-diastolic
diameter; LVEF, left ventricular ejection fraction; LVH, left ventricu-
lar hypertrophy; MPI, myocardial performance index; NS, not signif-
icant; SCD, sickle cell disease; TRV, maximal tricuspid regurgitation
velocity.
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